logo
US Supreme Court expected to rule on Obamacare preventive care task force

US Supreme Court expected to rule on Obamacare preventive care task force

Reuters3 hours ago

WASHINGTON, June 27 (Reuters) - The U.S. Supreme Court is expected to rule on Friday on the legality of a key element of the Obamacare law, formally called the Affordable Care Act, that helps guarantee that health insurers cover preventive medical care such as cancer screenings at no cost to patients.
The federal government has appealed a lower court's determination that the U.S. Preventive Services Task Force, which under Obamacare has a major role in choosing what services will be covered, is composed of members who were not validly appointed. Its 16 members are appointed by the U.S. secretary of health and human services without Senate confirmation.
Several individual Christian plaintiffs and two small businesses sued in federal court in Texas in 2020 to challenge the task force's structure. It was the latest in a years-long series of challenges to Democratic former President Barack Obama's signature legislative achievement to reach the Supreme Court.
Before the case was narrowed to the appointments issue, the plaintiffs had included a religious objection to being required to cover pre-exposure prophylaxis for HIV. They claimed that such drugs "facilitate and encourage homosexual behavior, prostitution, sexual promiscuity and intravenous drug use."
The U.S. government's appeal of the decision by the New Orleans-based 5th U.S. Circuit Court of Appeals initially was filed by Democratic former President Joe Biden's administration before being taken up by Republican President Donald Trump's administration.
Public health advocates had warned that life-saving tests and treatments that have been cost-free under most insurance plans may become subject to co-pays and deductibles, deterring many Americans from obtaining them, if the justices upheld the 5th Circuit's ruling.
A key question in the case was whether the task force wields power to such an extent that its members, under the Constitution's "appointments clause," are "principal officers" who must be appointed by the president and confirmed by the U.S. Senate or "inferior officers" not subject to these requirements.
The task force is made up of medical experts who serve four-year terms on a volunteer basis. It reviews medical evidence and public feedback and issues recommendations about which preventive services would be most effective for detecting illnesses earlier or addressing ailments before a patient's condition worsens.
The task force has identified, opens new tab dozens of preventive services as having a high or moderate net benefit to patients including screenings to detect diabetes and various types of cancer, statin medications to lower the risk of heart disease and stroke, and interventions to help patients quit smoking or unhealthy alcohol use.
The 5th Circuit ruled in 2024 that the task force's structure violates the Constitution, as the plaintiffs claimed.
The justices during April 21 arguments in the case posed questions over whether the law gives the HHS secretary the appropriate level of supervision over the task force, including the power to influence its recommendations and fire members at will, or if it operates as a largely independent governmental body whose recommendations effectively have the force of law.
The Justice Department urged the justices to view the task force's members as "inferior officers."
Hashim Mooppan, a Justice Department lawyer, told the justices that the HHS secretary can remove task force members at will, review their recommendations and prevent them from taking effect, and can require the task force to obtain his approval before it issues any recommendations.
The plaintiffs contended that the task force's lack of supervision and insulation from removal makes its members "principal officers."
The 5th Circuit's ruling also rejected the government's request to remove certain offending words from the Obamacare provision at issue - a process called severing - in order to make that part of the law conform to the Constitution.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

US Senator investigates GSK for pulling children's asthma inhaler
US Senator investigates GSK for pulling children's asthma inhaler

Reuters

time36 minutes ago

  • Reuters

US Senator investigates GSK for pulling children's asthma inhaler

WASHINGTON, June 27 (Reuters) - Democratic U.S. Senator Maggie Hassan said on Friday she is launching an investigation into British pharmaceutical giant GlaxoSmithKline's (GSK.L), opens new tab decision to discontinue a widely used asthma inhaler for children. In letters sent on Friday to GSK and its authorized generic distributor, Prasco Laboratories, and seen by Reuters, Hassan said the decision to remove Flovent HFA from the market in January 2024 had contributed to a spike in hospitalizations and deaths linked to asthma complications. She demanded documents detailing the rationale behind the decision, and its financial and health impacts. Hassan, the top Democrat on the Senate Finance Committee's Health Care Subcommittee, called on GSK to restore the inhaler to market. She also requested internal pricing documents, rebate data, and communications with regulators by July 18. She accused GSK of evading rebate obligations to Medicaid, which provides health coverage to 71 million low-income people and is one of the biggest U.S. safety-net programs. In addition, GSK's decision to replace the brand-name inhaler with a higher-cost authorized generic had lowered access for low-income patients, Hassan said. "Children across the country have faced life-threatening medical challenges and families have grappled with more expensive or less effective alternative medications — when these options are available at all," Hassan wrote in her letter. GSK told Hassan in response to an earlier letter she sent in May last year that Prasco controls pricing of the generic. Hassan said both companies failed to ensure affordability of the treatment, contributing to delays or denials of insurance coverage. Hassan cited a Johns Hopkins analysis which found that GSK's move saved the company $367 million in 2024 Medicaid rebates, while costing the program over $550 million. Parents reported paying up to $150 per inhaler for the generic, compared to $10 for Flovent. GSK said last year it would cap out-of-pocket costs for all its inhaled asthma and chronic lung disease medicines at $35 per month for eligible patients in the United States starting January 2025, following similar moves by its rivals. The announcement came after lawmakers criticized manufacturers over high prices, and launched an investigation, opens new tab to look into the prices at which these were sold in the U.S. versus other countries.

Cuomo to stay in New York mayoral race despite Mamdani besting him in primary
Cuomo to stay in New York mayoral race despite Mamdani besting him in primary

The Guardian

timean hour ago

  • The Guardian

Cuomo to stay in New York mayoral race despite Mamdani besting him in primary

Former New York governor Andrew Cuomo reportedly plans to run as an independent candidate in the New York City's mayoral race, days after finding himself bested in the Democratic primary by progressive insurgent candidate Zohran Mamdani. Several news outlets reported late on Thursday that Cuomo, 67, part of a long and powerful political dynasty in New York, would not withdraw after conceding the primary to democratic socialist newcomer Mamdani, who is now the favorite in the race and could become the city's first Muslim mayor at the general election in November. Cuomo is now expected to continue as an independent candidate on a 'Fight and Deliver' ballot line. But Cuomo has not decided whether to actively campaign in the coming months. The former governor, who stepped down in 2021 in the face of allegations of sexual harassment and bullying in the workplace, now joins the embattled incumbent mayor, Eric Adams, a Democrat who has relaunched his campaign as an independent. New York City was rocked politically on Tuesday night when Cuomo, who had at one point in the primary led Mamdani by 20 points, fell behind his rival by seven when a well-orchestrated campaign by the progressive candidate brought in passionate, younger voters not normally geared to mayoral primaries. Seeking to soothe the concerns of the business community over a platform that includes tax hikes on the wealthy, rent freezes and free city services, Mamdani, 33, told ABC News this week that 'there is a need for a new generation of leadership'. 'I think that the Democratic party must always remember what made so many proud to be Democrats, which is a focus on the struggles of working-class Americans across this country,' Mamdani told the outlet. Prominent Wall Streeters are wary. 'It's officially hot commie summer,' hedge fund billionaire Dan Loeb said on X after Mamdani's win. While news reports suggest that Cuomo is running, he has until the end of Friday to withdraw from his independent ballot line, according to the New York state board of elections calendar.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store